Desmopressin Acetate (DDAVP)

The following drug information is obtained from various newswires, published medical journal articles, and medical conference presentations.

Approval Status:

Approved March 1998

Specific Treatments:

nocturnal enuresis

Therapeutic Areas

General Information

A tablet formulation of DDAVP (desmopressin acetate) has been approved for managing primary nocturnal enuresis in patients age six and over. DDAVP is a synthetic form of vasopressin that has been available in nasal spray since 1989. Vasopressin regulates water balance and urine production.